share_log

Goldman Sachs Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $33

Benzinga ·  May 3 11:50

Goldman Sachs analyst Salveen Richter maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $29 to $33.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment